Eli Lilly's $3 Billion China Bet on GLP-1 Supply Chain Amplifies Strategic Risks

What happened

Eli Lilly announced a $3 billion investment over the next decade to expand supply chain and production capacity in China for the oral GLP-1 drug orforglipron, targeting type-2 diabetes and obesity markets. This move aligns with the aggressive capital allocation highlighted in the DeepValue report, which notes sustained high capex for manufacturing buildout ahead of key launches. Given that GLP-1 drugs like Mounjaro and Zepbound now represent 56% of Lilly's revenue, securing reliable supply is critical to meeting anticipated demand and avoiding shortages that have plagued competitors. However, the report warns of significant risks, including potential net-price erosion from U.S. policy actions and high inventory levels that could lead to write-downs if launch demand disappoints. Thus, while the China investment underscores Lilly's commitment to scaling its franchise, it does little to mitigate core valuation concerns tied to pricing pressure and the upcoming FDA decision.

Implication

The $3 billion investment extends Lilly's high-capex cycle, potentially delaying free cash flow generation while adding geopolitical exposure in China. It underscores the company's bet on oral GLP-1 success, but success depends critically on FDA approval by April 2026 and early prescription velocity matching Novo's benchmark of 26,109 weekly scripts. If pricing pressures emerge as management warns, the fixed costs from this expansion could exacerbate margin compression, especially given the concentrated revenue base in GLP-1s. Moreover, the investment does little to counter tolerability concerns that could limit orforglipron's real-world persistence. Therefore, investors should view this as a necessary but risky step that reinforces the need for caution until launch outcomes are clear.

Thesis delta

The investment does not materially shift the investment thesis, which remains centered on the oral GLP-1 launch and net-price stability. It reinforces Lilly's supply-side preparations but introduces additional capital at risk in a foreign market, without altering the fundamental need for FDA approval and pricing resilience. Consequently, the key triggers—regulatory approval and early script data—are unchanged, and the 'WAIT' rating is still warranted.